Ribbon Biolabs develops a proprietary automated enzymatic DNA synthesis platform guided by combinatorial optimization algorithms to assemble long, sub-genomic DNA molecules. The company validated its capabilities by producing a 10,000 bp molecule in May 2021 and a 20,000 bp molecule in December 2021. Founded in 2018 and operating from Vienna and the IST Park, Ribbon positions its technology for biopharmaceutical research and broader synthetic biology applications. The business is commercializing its platform and plans to set up production facilities with key technology partners. The company is preparing for expansion into the US market and has ambitious hiring plans for operational and scientific roles. Its recent financing provides capital to scale production and support commercialization activities.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2022